Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …

Most of the contraindications to the administration of intravenous (IV) recombinant tissue
plasminogen activator (rtPA) originated as exclusion criteria in major stroke trials. These …

Background and Purpose—The authors present an overview of the current evidence and
management recommendations for evaluation and treatment of adults with acute ischemic …

Книга посвящена актуальнейшей медико-социальной проблеме современности
острым и хроническим прогрессирующим нарушениям мозгового кровообращения …

Although intravenous administration of tissue plasminogen activator is the only proven
treatment after acute ischemic stroke, there is always a concern of hemorrhagic risk after …

Background: We evaluated the management, outcome and haemorrhagic risk in a cohort of
ischaemic stroke patients with mild symptoms treated with intravenous tissue plasminogen …

Objectives: This study sought to randomly compare cerebral protection with ANGIOGUARD
(Cordis Corporation, Bridgewater, New Jersey) with Mo. Ma (Invatec/Medtronic Vascular Inc …

Hintergrund: Ziel dieses Manuskripts ist ein Update der DGN-Leitlinie zu rekanalisierenden
Therapien bei Patienten mit akutem Hirninfarkt, was sowohl die systemische Thrombolyse …

Introduction Despite increasing evidence of its efficacy in advanced age or in mild or severe
strokes, intravenous thrombolysis remains underused for acute ischaemic stroke (AIS). Our …

Introduction iv Thrombolysis (IVT) is the most important achievement of the last 20 years in
the field of ischemic stroke management. In Italy, the evidence that stroke units were …